Cloudflare (NYSE:NET) stock keeps pushing higher, even though its valuation is in nosebleed territory. I want to recommend investors buy NET stock, but I can’t do that in good conscience. In fact, at this point, the only thing I can do is point out how incredibly overvalued it seems to be, even as it continues
Stocks to sell
Lemonade (NASDAQ:LMND) stock has caught investors’ attention, and for pretty good reason. Source: Stephanie L Sanchez / Shutterstock.com If Amazon’s (NASDAQ:AMZN) taught us anything over the past few decades, it’s the power of disruption, and the value of recognising it early. That’s part of the reason that insurance disruptor Lemonade is so attractive. LMND stock
Cloudflare (NYSE:NET) stock has performed extremely well in 2021. As of Oct. 20, it’s up 130%, opening at $175.80. With this in mind, many investors think that there are only two scenarios for NET stock. Either this momentum will continue, sending prices higher, or more prudent, conservative investors and traders will wait for a dip
Olaplex (NASDAQ:OLPX) just had a unique IPO on Sept. 30. The IPO price of $21 resulted in a huge capital raise of $1.78 billion from the sale of OLPX stock. However, as opposed to almost every other IPO there is, this capital raise is going straight to the pockets of the existing private equity owners,
UiPath (NYSE:PATH) is a $25.79 billion technology stock that is draining out cash and seems to be having trouble with top-line growth. This means that the company may have trouble maintaining this high valuation. As a result, PATH stock is likely to keep falling. Source: dennizn / Shutterstock.com In fact, from its peak of $85.00
After months of sideways price action, Covid-19 vaccine play Ocugen (NASDAQ:OCGN) stock is zooming higher once. Source: shutterstock.com/PhotobyTawat The big development is a likely Emergency Use Listing (EUL) from the World Health Organization (WHO) for Covaxin. Developed in India by Bharat Biotech, Ocugen holds the U.S. and Canadian rights to market this vaccine. An EUL certainly
Just over a year ago, Hyliion (NYSE:HYLN) was one of the hottest electric vehicle special-purpose acquisition company (SPAC) plays out there. Just before its “de-SPACing,” excitement over this maker of electric trucks and powertrains briefly sent HYLN stock to prices over $50 per share. Source: Shutterstock Flash forward back to now, and where are shares changing
With some big moves, Camber Energy (NYSE:CEI) stock has garnered the attention of investors and speculators. At the beginning of September, CEI stock was trading as low as 45 cents. Since then, the stock has touched highs of $4.85. However, the speculative surge in the stock was dented by a negative report from Kerrisdale Capital.
OpenDoor (NASDAQ:OPEN) stock is the kind of name I’ve learned to avoid. Source: PREMIO STOCK/Shutterstock.com Over my years of investing, I’ve learned–in some cases, the hard way — that buying stocks on weakness is really the best and easiest way to make money in the market. Conversely, buying risky names that are riding positive momentum
Tech stocks are hot property in 2021 but that is not the case with Intel (NASDAQ:INTC) stock. Source: Pavel Kapysh / Shutterstock.com The stock started diving a long time ago and has continued to do so for the past few months. INTC stock managed to hit an all-time high of $68 in January 2020 and
A few months ago, the Federal Reserve was talking about “transitory” inflation. The governors at the Fed meant that while inflation was rising swiftly, it wasn’t going to last. But inflation kept rising at a brisk clip and the Fed started to be less sanguine about the transitory nature of inflation. It hedged by telling
Ocugen (NASDAQ:OCGN) is a small biotech firm. For years, it tried unsuccessfully to commercialize therapies for eye diseases. However, in 2020, it ended a Phase 3 trial on that front and pivoted to Covid-19. Its first effort in that regard, Covid-19 testing, totally failed to take off. The company is nothing if not persistent, however,
I fully understand why it’s very tempting to buy Alibaba (NASDAQ:BABA) stock at this point. The company’s shares have tumbled a great deal in the last six months, yet the company remains one of the biggest and most successful e-commerce players on the planet, and its cloud business is still growing rapidly. Source: BigTunaOnline /
With shares moving up following the acquisition of Nanotech, is it time to buy Meta Materials (NASDAQ:MMAT) stock, ahead of its revenues taking off? Not so fast. It’s still down big from the high prices it hit when it first appeared on the radar of meme stock investors. But at $5.31 per share, this smart
Israeli online freelancer platform Fiverr (NYSE:FVRR) is the definition of a mixed bag. The company has some key strengths that are balanced out by some equally important weaknesses. I typically find it’s best to avoid companies like this unless their shares are trading at a very attractive valuation. In the case of FVRR stock, that
There are a few reasons why investors piled into Clover Health (NASDAQ:CLOV) stock this year. It was a popular SPAC stock headed by the charismatic Chamath Palihapitaya. And its Jan. 8 merger with Social Capital Hedosophia, a SPAC, made many investors aware of the company. Clover is a Medicare insurance services provider. Source: Shutterstock But
Zoom Video Communications (NASDAQ:ZM) was one of the prime beneficiaries of the coronavirus pandemic. It closed out 2020 with a colossal run rate of $3.5 million in revenues. However, judging from recent results, its top- and bottom-line growth are slowing as we inch closer to a post-pandemic reality. Moreover, ZM stock is incredibly overvalued based
When you have nearly 3 billion monthly active users, some things are bound to go wrong. As the adage goes, you can please some of the people all of the time, you can please all of the people some of the time, but you can’t please all of the people all of the time. That
To put it succinctly, there isn’t very much making Lemonade (NYSE:LMND) stock attractive at present. Source: Stephanie L Sanchez / Shutterstock.com Yes, there’s news that the insurance company is launching a new service for pets. That will expand the company’s product mix beyond life, homeowners, and renters insurance. And Lemonade already announced a car insurance
Meta Materials (NASDAQ:MMAT), a Canadian company that develops nanocomposite materials and products, just closed on its first major acquisition in the nanotech field. The good news is that this acquisition will bring in much more revenue than the measly $624,000 Meta Materials made in its second quarter. The bad news is that the highly inflated
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 31
- Next Page »